Tumor Microenviornment Organoids for
MOA analytics and immunotherapy development.

FDA sets a clear mission - to replace animal testing with organoids and AI approaches.

Cypre builds high-throughput, human-derived organoids that replicate the tumor, immune, and stromal compartments of the tumor microenvironment (TME).

Our platform enables mechanism of action insights and supports the discovery of next-generation immunotherapies.

FDA Announcement

April 10, 2025 — FDA Redefines Preclinical Standards
FDA encourages the replacement of animal models with organoid and AI systems.
— Dr. Makary, FDA Commissioner

With over 90% of drugs failing in clinical trials, the time to modernize preclinical models is now.
At Cypre, we commend the FDA and the US Government for their leadership through the Modernization Act 2.0 and are proud to support this shift with our immune-integrated organoid platform.

Tumor Microenviornment Organoids for MOA analytics and immunotherapy development.

FDA sets a clear mission - to replace animal testing with organoids and AI approaches.

Cypre builds high-throughput, human-derived organoids that replicate the tumor, immune, and stromal compartments of the tumor microenvironment (TME).

Our platform enables mechanism of action insights and supports the discovery of next-generation immunotherapies.

Tumor Microenviornment Organoids for
MOA analytics and immunotherapy development.